( f C. difficile strain Z. Jiang M.D...)Salix Pharmaceuticals Previews Digestive Disease Week 2007,Health

f C. difficile strain Z. Jiang, M.D. May 20 isolated from patients with hospital- associated diarrhea The effect of selective intestinal A. Saveriadis, M.D. May 20 decontamination on liver hemodynamics in patients with alcohol related decompensated cirrhosis Restless leg syndrome in patients with L. Weinstock, M.D. May 21 irritable bowel disease: response to bacterial overgrowth therapy Small intestinal bacterial overgrowth in L. Weinstock, M.D. May 21 patients with interstitial cystitis and gastrointestinal symptoms Double blind, randomized study to M. Lukas, M.D. May 22 evaluate efficacy and urinary excretional rate of two doses of rifaximin-EIR in mild to moderate active Crohn's disease (GRACE 02 study) Rifaximin as a steroid-sparing T. Shah, M.D. May 23 medication in the management of patients with mild to moderate inflammatory bowel disease Decreasing rates of colectomy despite M. Issa, M.D. May 23 high rates of hospitalization in C. difficile infected IBD patients: a tertiary referral center experience MOVIPREP Better efficacy of a new 2-liter bowel L. Clark May 22 cleansing preparation in the ascending colon Randomised and controlled clinical trial H. Gruss May 23 of polyethylene glycol with electrolytes and ascorbic acid in comparison to sodium phosphate for bowel preparation before colon cancer screening colonoscopy COLAZAL Efficacy and safety of balsalazide for J. Quiros May 22 treatment of pediatric patients with mild to moderate ulcerative colitis: A randomized double-blind study

CONTINUING MEDICAL EDUCATION ACTIVITES

In addition, Salix is supporting, through an unrestricted educational grant, two continuing medical education activities in conjunction with DDW this year: -0-

"Navigating the
'"/>




Page: 1 2 3 4 5 
Related medicine technology :

1. Salix Pharmaceuticals Announces Positive Top Line Results of
Balsalazide Tablets Registration Study
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird
Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II
Study of its Factor Xa Inhibitor at the XXI Congress of the
International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for
Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging
Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin
Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin
Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials &
Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III
Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results
and Additional Oral and Poster Presentations at the XXI Congress of
the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib
Combination Studies